Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CZ4D
- Development stage
- Unknown
- Lead developer
- Zhejiang Cuize Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
CZ4D is a small molecule drug developed by Zhejiang Cuize Pharmaceutical Technology. It is formulated as an inhalation powder and is currently in Phase 1 clinical trials. The primary therapeutic areas under investigation are infectious diseases and respiratory diseases, with the main active indication being pulmonary aspergillosis. Clinical studies are evaluating its safety, tolerability, and pharmacokinetic characteristics in both healthy subjects and patients with mild to moderate stable asthma. The mechanism of action and molecular target have not been publicly disclosed as of the latest update[1].
- Brand names
- CZ4D吸入粉雾剂
- Other names
- CZ4D吸入粉雾剂
Beyond the preview
Go deeper on CZ4D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CZ4D.